| pubmed-article:10916103 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10916103 | lifeskim:mentions | umls-concept:C0017661 | lld:lifeskim |
| pubmed-article:10916103 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:10916103 | lifeskim:mentions | umls-concept:C1704264 | lld:lifeskim |
| pubmed-article:10916103 | lifeskim:mentions | umls-concept:C0678951 | lld:lifeskim |
| pubmed-article:10916103 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10916103 | pubmed:dateCreated | 2000-9-7 | lld:pubmed |
| pubmed-article:10916103 | pubmed:abstractText | It is evident that cytokines play an important role in the pathogenesis as well as disease progression in IgA nephropathy (IgAN). The level of cytokine production is influenced by different genotypes that reflect gene polymorphism of the pertinent cytokine. Interleukin-1 receptor antagonist (IL-1ra) and tumor necrosis factor-alpha (TNF-alpha) gene polymorphism have been found to affect disease susceptibility and activity in several inflammatory diseases. However, the impact of these polymorphisms in IgAN patients has not previously been thoroughly studied. | lld:pubmed |
| pubmed-article:10916103 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10916103 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10916103 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10916103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10916103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10916103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10916103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10916103 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10916103 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:10916103 | pubmed:issn | 0085-2538 | lld:pubmed |
| pubmed-article:10916103 | pubmed:author | pubmed-author:LeeS HSH | lld:pubmed |
| pubmed-article:10916103 | pubmed:author | pubmed-author:WuM JMJ | lld:pubmed |
| pubmed-article:10916103 | pubmed:author | pubmed-author:ChengC HCH | lld:pubmed |
| pubmed-article:10916103 | pubmed:author | pubmed-author:LianJ DJD | lld:pubmed |
| pubmed-article:10916103 | pubmed:author | pubmed-author:ShuK HKH | lld:pubmed |
| pubmed-article:10916103 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10916103 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:10916103 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10916103 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10916103 | pubmed:pagination | 783-9 | lld:pubmed |
| pubmed-article:10916103 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:meshHeading | pubmed-meshheading:10916103... | lld:pubmed |
| pubmed-article:10916103 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10916103 | pubmed:articleTitle | Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. | lld:pubmed |
| pubmed-article:10916103 | pubmed:affiliation | Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taiwan. khshu@vghtc.vghtc.gov.tw | lld:pubmed |
| pubmed-article:10916103 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10916103 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:60582 | entrezgene:pubmed | pubmed-article:10916103 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10916103 | lld:pubmed |
